Symetrica wins the Venture category at the BVCA South West Management Team Awards 2017

May 5th, 2017|

Symetrica have been announced as the winner of the Venture Category at the British Private Equity & Venture Capital Association’s (BVCA) South West Management Team Awards 2017. Now in their ninth year, the BVCA Management Team Awards recognise and reward brilliant businesses up and down the country that are backed by UK private equity and venture capital investors.

The BVCA’s judges’ commented: “Symetrica has been a pioneer in its radiation detection technology and now has a leading position in homeland security. The judges were impressed with the way Heddwyn Davies had grasped this opportunity in 2016, driving a fourfold increase in sales, notably breaking into the US market, while at the same time bringing out a handheld version of the technology.”

Symetrica will now go forward into the national final to compete against the other UK regions before the national winners are announced at the BVCA Gala Dinner on 30 November in London.

http://www.symetrica.com

BVCA Management Team Awards

[Read More]

Atlas Genetics raises $35m in Series D fundraising

February 1st, 2017|

Financing global launch and menu development of Atlas Genetics’ io® molecular testing system

Atlas Genetics Ltd., the ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces completion of its Series D financing, raising $35 million from a syndicate including all Series C Investors and one new investor, Wondfo Biotech.

Development of the Atlas Genetics io® system has been completed with the successful CE marking of the Chlamydia trachomatis (CT) test announced in February 2016.  This new Series D equity issue will finance the clinical trials and commercial launch of a second test, for detection of both Chlamydia and Gonorrhoea, planned for regulatory approvals in the US around the end of 2017, as well as further development of additional diagnostics menu.  The financing also provides funding to expand cartridge manufacturing capacity at Bespak, Atlas Genetics’ cartridge manufacturing partner.

[Read More]

Micrima raises £2.6 million for ground-breaking radiowave breast imaging technology

September 5th, 2016|

Micrima, the Bristol-based breast imaging company and developer of a ground-breaking and CE Mark approved radiowave breast imaging system, has successfully closed on a new financing round of £2.6m. The new funding will support accelerated development of its patented MARIA technology, which aims to enable breast screening to become safer, more comfortable and more accessible to a larger proportion of the global female population. The company intends to start the commercialisation of its first system towards the end of this year.

“Breast cancer is the most common cause of death in women between the ages of 35 and 55 in Europe and the leading cause of death for women in many countries. The problem is that many tumours are not discovered early enough, largely due to the difficulty in discriminating between cancers and dense tissue using current imaging technology,” said Roy Johnson, Micrima’s Executive Chairman. “Using harmless radiowaves, the MARIA imaging system is capable of detecting tumours in dense tissue and allows routine and repeated scanning without any of the safety or comfort concerns associated with x-ray mammography. The process takes less than five minutes and avoids painful breast compression.”

[Read More]

Covalent Software Limited acquired by Ideagen Plc

August 8th, 2016|

TVP portfolio company, Covalent Software, has been acquired by Ideagen Plc, the UK AIM listed provider of information management software to regulated industries.

For Covalent the deal provides significant future growth opportunities in its core financial and public services markets as well as opportunities for the enlarged group to expand its governance, risk and compliance (GRC) presence in healthcare, local government, finance and banking.

The deal marks a successful exit for Covalent’s previous funders. TVP’s Nick Simmonds said: “It has been a pleasure working with Peter McHugh and the team at Covalent Software and we are delighted with the way in which Covalent has developed into a technology leader in the GRC space.  We wish the company every success for the future.”

[Read More]

Atlas Genetics Gains EU CE Approval for First Product

February 9th, 2016|

Approval of Chlamydia test for marketing and sale in Europe

Atlas Genetics Ltd, the Bath, UK based, ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces that it has received approval to CE Mark its Chlamydia trachomatis (CT) test to be launched on the Company’s io® platform.  By meeting the requirements of the IVD Directive (98/79/EC), the CT test is now cleared for sale within the European Union.

The launch of the io® CT test signals a new era in ultra-rapid molecular diagnostics.  This is the first molecular POC test for a Sexually Transmitted Infection (STI) to enter the market, capable of delivering test results in just 30 minutes.  With the speed and accuracy of the io® CT product, the testing and treatment of patients within a single, brief visit to the clinic now becomes a reality.

[Read More]

Sky partners with Object Matrix

February 2nd, 2016|

Object Matrix, the trusted storage partner to the media and entertainment industries, today announces that Sky, Europe’s leading entertainment company with over 21 million customers, has integrated MatrixStore object storage into Avid Interplay production workflows at its headquarters in London.

Sky is Europe’s leading investor in television content, with a combined programming budget of £4.9bn, commissioning its own original programming and entering into strategic partnerships to deliver the best possible TV viewing experience for customers. With production infrastructure often used to capacity, the Sky production team looked to find a solution that could not only scale into future workflows but also take the strain off the editing storage with seamless integration into current workflows.

[Read More]

Symetrica’s Radiation Detection and Identification Technology to be deployed by US Department of Homeland Security

January 28th, 2016|

Symetrica has announced that its patented radiation detection and identification technology will be deployed in the latest Handheld Radioisotope Identification Devices (RIIDs) that Smiths Detection Inc. has agreed to supply to the U.S. as part of a contract with the Department of Homeland Security (DHS). Symetrica’s Discovery Technology is at the heart of the Smiths Detection RadSeeker handheld radiation detectors for which the DHS Domestic Nuclear Detection Office (DNDO) recently awarded an IDIQ (indefinite delivery/indefinite quantity) contract with a maximum value of $143 million for the technology, its maintenance and associated training.

[Read More]

Technology Venture Partners appoints Richard Green as Non-executive Chairman

July 16th, 2015|

Technology Venture Partners the technology venture capital firm has announced the appointment of Richard Green as Non-executive Chairman.

Richard Green joined Kleinwort Benson Development Capital in 1988 and was a founder in 2001 of the spin-out business which became August Equity LLP, where he was the Managing Partner until 2009 and then Chairman until his retirement in April 2014.  He is a past chairman of the British Venture Capital Association and is currently a non-executive director of AIM-quoted Qannas Investments Limited, a non-executive director of Northern Venture Trust PLC, a member of the Advisory Board of Finance for Business North East and a member of the Advisory Committee of the European Investment Bank’s Growth Finance Initiative.

[Read More]

Symetrica Appoints David Price As Chairman

June 23rd, 2015|

Symetrica, the Technology Venture Partners portfolio company providing radiation detection solutions company has announced the appointment of David Price as Non-executive Chairman.

David Price was formerly CEO of Chemring Group plc, the FTSE 250 listed with revenues of £600m. Chemring is a specialist manufacturer of expendable countermeasures, advanced electronics and energetic materials for the global defence, security and safety markets. Prior to Chemring, David was MD of Rolls Royce Naval Marine, a division supplying propulsion systems, products & services to 59 navies for both submarine and surface ship applications. Naval Marine is a global business with a turnover of over £450m per year and employing 2900 staff. It undertook the design authority role for all Royal Navy nuclear reactor systems and manufactured all of the key components for the Pressurised Water Reactor.

[Read More]

Micrima’s radiowave breast cancer detection system gains EU regulatory approval

April 29th, 2015|

Micrima, the Bristol company developing a safe, low-cost way of improving breast cancer detection, has gained CE marking for its MARIA (Multistatic Array processing for Radiowave Image Acquisition) product, paving the way for further supportive clinical trials in the UK and expansion into Europe.

[Read More]